Results 1 to 10 of about 17,357 (235)

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials

open access: yesFrontiers in Neurology, 2023
BackgroundThe optimal dose of tenecteplase vs. alteplase for acute ischemic stroke (AIS) has yet to be established. Therefore, we included the latest randomized controlled trials (RCT) to assess the efficacy and safety of different doses of tenecteplase ...
Huo Liang   +8 more
doaj   +2 more sources

Replacing Alteplase with Tenecteplase: Is the Time Ripe?

open access: yesJournal of Stroke, 2023
Thrombolysis for acute ischemic stroke has predominantly been with alteplase for over a quarter of a century. In recent years, with trials showing evidence of higher rates of successful reperfusion, similar safety profile and efficacy of tenecteplase (TNK) as compared to alteplase, TNK has now emerged as another potential choice for thrombolysis in ...
Nishita Singh   +5 more
openaire   +4 more sources

Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review

open access: yesInternational Journal of Emergency Medicine, 2022
Introduction Thrombolysis for acute ischemic stroke (AIS) with alteplase is the currently approved therapy for patients who present within 4.5 h of symptom onset and meet criteria.
Neha Potla, Latha Ganti
doaj   +2 more sources

Predictors of the unfavorable outcomes in acute ischemic stroke patients treated with alteplase, a multi-center randomized trial

open access: yesScientific Reports
Worldwide, stroke is a leading cause of long-term disability in adults. Alteplase is the only approved treatment for acute ischemic stroke (AIS) and results in an improvement in a third of treated patients.
Mohamed G. Zeinhom   +7 more
doaj   +2 more sources

Argatroban plus alteplase in posterior versus anterior circulation stroke [PDF]

open access: yesAnnals of Clinical and Translational Neurology
Objective ARAIS trial failed to demonstrate benefit of argatroban as an adjunct to alteplase for stroke. Given differences between anterior circulation stroke (ACS) and posterior circulation stroke (PCS), we performed prespecified secondary analysis to ...
Yu Cui, Hui‐Sheng Chen
doaj   +2 more sources

Effects of alteplase in the treatment of acute ischemic stroke

open access: goldInternational Journal of General Medicine, 2012
Josef YayanDepartment of Internal Medicine, Vinzentius Hospital, Landau, GermanyBackground: For the last 15 years, alteplase (recombinant tissue plasminogen activator) has been used widely throughout the world for the treatment of acute ischemic stroke ...
Yayan J
doaj   +3 more sources

Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial [PDF]

open access: yesStroke and Vascular Neurology
Background In ischaemic stroke, minor deficits (National Institutes of Health Stroke Scale (NIHSS) ≤5) at presentation are common but often progress, leaving patients with significant disability.
Dar Dowlatshahi   +28 more
doaj   +2 more sources

Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials

open access: yesAnnals of Medicine
Objectives Tenecteplase, a modified variant of alteplase with greater fibrin specificity and longer plasma half-life, may have better efficacy and safety than alteplase in patients with acute ischemic stroke (AIS).
Jian Huang   +4 more
doaj   +2 more sources

Alteplase (TPA) for Clotted Dialysis Catheters [PDF]

open access: bronzeThe International Journal of Artificial Organs, 2000
S C Hathiwala, V Khalili, I Hristea
openaire   +5 more sources

Alteplase licensed for catheter clearance [PDF]

open access: bronzeAmerican Journal of Health-System Pharmacy, 2001
Cheryl A. Thompson
openaire   +3 more sources

Home - About - Disclaimer - Privacy